Bluejay Diagnostics 株価情報 (NASDAQ: BJDX)

最新ニュース Bluejay Diagnostics (NASDAQ:BJDX) 株価情報

Bluejay Diagnostics

Bluejay Diagnostics Inc is a medical diagnostics company. It is developing rapid tests using whole blood using its Symphony technology platform to improve patient outcomes in critical care settings. The company's first product, the Symphony IL-6 test, is for the monitoring of disease progression in critical care settings and is a clinically established inflammatory biomarker for the assessment of the severity of infection and inflammation across many disease indications, including sepsis.

Bluejay Diagnostics Inc

WIIM

NTNX

Nutanix shares are trading higher after the company reported better-than-expected Q1 financial results. Also, Needham and Northland Capital Markets raised their respective price targets on the stock.

HP shares are trading lower after the company reported Q4 financial results and issued Q1 adjusted EPS guidance below estimates.

Baird analyst Mark Altschwager maintains Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) with a Neutral and raises the price target from $47 to $49.

News

Price Target

Analyst Ratings

URBN

Baird Maintains Neutral on Urban Outfitters, Raises Price Target to $49

Small Cap Consumer Research analyst Eric Beder maintains Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) with a Buy and lowers the price target from $29 to $23.

Small Cap Consumer Research Maintains Buy on Guess, Lowers Price Target to $23

Earnings

SGBX

Safe & Green Holdings Q3 EPS $(1.78), Sales $1.75M Down From $4.00M YoY

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2024/11/26/final-trades-amazon-charter-lockheed-martin-rockwell-automation.html">Halftime Report Final Trades</a>,&#8221; Joshua Brown of Ritholtz Wealth Management said Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) <a href="https://www.benzinga.com/quote/AMZN/analyst-ratings">looks good.</a>
On Tuesday, Redburn Atlantic analyst Alex Haissl maintained Amazon with a Buy and raised the price target from $225 to $235, while MoffettNathanson analyst Michael Morton maintained the stock with a Buy and increased the price target from $235 to $248.
Karen Firestone of Aureus Asset Management said three good things are happening in Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>), i.e. increasing subs, lower capex and buying stock back.
On Nov. 13, Charter Communications announced it would acquire Liberty Broadband in an all-stock transaction.
<ul>
<li>Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a></li>
</ul>
Jim Lebenthal of Cerity Partners named Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) as his final trade.
On Oct. 22, the company reported net sales growth of 1.3% year-over-year to $17.104 billion, missing the consensus of $17.351 billion. Adjusted EPS of $6.84, up from $6.77 in the prior year, topped the consensus of $6.50.
Stephanie Link of Hightower picked Rockwell Automation, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>).
On Tuesday, Baird analyst Richard Eastman maintained Rockwell Automation with an Outperform rating and raised the price target from $290 to $305.
Price Action:
<ul>
<li>Amazon shares gained 3.2% to close at $207.86 on Tuesday.</li>
<li>Charter Communications shares gained by 1.5% to settle at $390.29 during Tuesday's session.</li>
<li>Lockheed Martin shares fell by 0.1% to close at $521.45 during Tuesday's session.</li>
<li>Rockwell Automation fell by 0.9% to settle at $296.00 during the session.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42188912/jim-cramer-linde-is-a-terrific-company-sees-another-stock-up-75-as-not-done">Jim Cramer: Linde Is A &#8216;Terrific&#8217; Company, Sees Another Stock Up 75% As &#8216;Not Done&#8217;</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Long Ideas

Markets

Media

Trading Ideas

AMZN

CHTR

Amazon, Lockheed Martin, Rockwell Automation And A Major Telecommunications Stock On CNBC's 'Final Trades'

Shares of&nbsp;Dell Technologies Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) fell sharply by 11.46% in pre-market trading on Wednesday, as per <a href="https://pro.benzinga.com/">Benzinga Pro</a>. This significant decline was triggered by the company&#8217;s release of a revenue forecast that failed to meet market expectations.
On Tuesday,&nbsp;Dell&nbsp;announced its projection for fourth-quarter revenue, estimating it to be&nbsp;between $24 billion and $25&nbsp;billion. This forecast was below the average analyst expectation of $25.57 billion by <a href="https://www.londonstockexchange.com/market-stock/0A7D/dell-technologies-inc/overview">LSEG</a>. The forecast for the upcoming quarter&#8217;s revenue and earnings did not meet Wall Street&#8217;s expectations, even though the company expressed optimism about AI sales growth.
Meanwhile, based on the ratings of 22 analysts compiled by Benzinga, the company has a consensus price target of $121.73. The three most recent analyst ratings by Evercore ISI Group, Wells Fargo, and Morgan Stanley on Nov. 20, Nov. 18, and Nov. 11, respectively estimated an average price target of $154.67, implying a 23.62% upside for Dell.
<figure class="wp-block-image size-large"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/27080021/Screenshot-2024-11-27-at-6.26.49%E2%80%AFPM-1024x375.png" alt="" class="wp-image-667284" /></figure>
The company&#8217;s quarterly revenue <a href="https://www.benzinga.com/news/earnings/24/11/42201885/dell-technologies-shares-drop-after-q3-revenue-misses-estimates-details">was reported at $24.37 billion</a>, which was below&nbsp;the consensus estimate of $24.65&nbsp;billion, yet it showed an increase from $22.25 billion in&nbsp;the same period last year.&nbsp;The company exceeded earnings expectations for the third quarter, reporting $2.15 per share compared to the consensus estimate of $2.05.
Read Also:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/11/42153356/is-warren-buffett-preparing-for-a-market-downturn-with-berkshire-hathaways-325b-cash-pile-analyst-says-internet-bubble-and-2008-crash-may-have-lessons?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Is Warren Buffett Preparing For A Market Downturn With Berkshire Hathaway&#8217;s $325B Cash Pile? Analyst Says&nbsp;Internet Bubble And 2008 Crash May Have Lessons</a></li>
</ul>
Disclaimer: This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.
Photo: Moment Capsule/Shutterstock.com

Equities

General

DELL

Dell Plunges 11% In Pre-Market On Wednesday After Q4 Forecasts Falls Short Of Wall Street Estimates

FTC Solar,&nbsp;Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTCI#NASDAQ">FTCI</a>) ("FTC Solar"), a leading provider of solar tracker systems, today announced that it will implement a reverse stock split of its issued and outstanding Common Stock at a ratio of 1-for-10, effective at 5:00 PM Eastern Time on November&nbsp;29, 2024, to satisfy the Nasdaq Capital Market's minimum $1.00 bid price per share requirement. The reverse stock split will be effected simultaneously for all outstanding shares of the Company's Common Stock and will affect all of the Company's stockholders uniformly.
FTC Solar's Common Stock will continue to trade on the Nasdaq Capital Market under the Company's existing trading symbol "FTCI" and will begin trading on a split-adjusted basis at the commencement of trading on December 2, 2024. The new CUSIP number for the common stock following the reverse split will be: 30320C&nbsp;301.

Stock Split

FTCI

FTC Solar Announces 1-For10 Reverse Stock Split, Will Begin Trading On A Split-Adjusted Basis At The Commencement Of Trading On December 2, 2024

Jefferies analyst Omar Nokta maintains Frontline (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) with a Buy and maintains $26 price target.

Jefferies Maintains Buy on Frontline, Maintains $26 Price Target

Baird analyst Mark Altschwager maintains Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) with a Outperform and raises the price target from $315 to $330.

BURL

Baird Maintains Outperform on Burlington Stores, Raises Price Target to $330

ABL Technologies, LLC ("ABL Tech"), a groundbreaking technology platform that revolutionizes how organizations manage and reconcile mortality data, and a subsidiary of Abacus Life, Inc. ("Abacus") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABL#NASDAQ">ABL</a>), today announced it is providing a preferred equity investment to Insured Connect, an insurance data and technology platform that connects carriers, distributors and agents. This investment will enable Insured Connect to meet the growing demand for its innovative data &amp; technology, while solidifying Abacus's growth in innovative technology related to longevity and distribution of new insurance products.

Abacus Life's ABL Tech Announces It Is Providing A Preferred Equity Investment To Insured Connect, An Insurance Data And Technology Platform That Connects Carriers, Distributors And Agents

Baird analyst Timothy Wojs maintains American Woodmark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMWD#NASDAQ">AMWD</a>) with a Outperform and raises the price target from $115 to $118.

AMWD

Baird Maintains Outperform on American Woodmark, Raises Price Target to $118

— Dosing Regimen to be Evaluated in Recently Initiated RLYB212 Phase 2 Clinical Trial —
Rallybio Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the publication of a manuscript titled, "Informing Pregnancy Dose via Target-Mediated Drug Disposition Modeling and Simulations for a Recombinant Human Monoclonal Antibody," in a special pregnancy themed issue of Clinical Pharmacology and Therapeutics: Pharmacometrics &amp; Systems Pharmacology.

Biotech

RLYB

Rallybio Announces Publication Of Target-Mediated Drug Disposition Modeling And Simulations Informing The RLYB212 Dosing Regimen In Pregnant Women; Dosing Regimen To Be Evaluated In Recently Initiated RLYB212 Phase 2 Clinical Trial

Aim Immunotech Announced Cash Conservation Plan; Independent Board Members To Receive 100% Of Director Compensation In Aim Stock

Across the recent three months, 11 analysts have shared their insights on Victoria's Secret (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSCO#NYSE">VSCO</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Victoria's Secret and provided 12-month price targets. The average target is $28.18, accompanied by a high estimate of $40.00 and a low estimate of $19.00. This current average reflects an increase of 19.2% from the previous average price target of $23.64. 
<img src="https://www.benzinga.com/files/images/story/2024/1732712505_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Victoria's Secret by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$40.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Corey Tarlowe</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$40.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$33.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Simeon Siegel</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$33.00</td>
<td>$29.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$27.00</td>
<td>$27.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$25.00</td>
<td>$23.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$23.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Jonna Kim</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Hold</td>
<td>$26.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Adrienne Yih</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$23.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Sell</td>
<td>$19.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Alice Xiao</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$21.00</td>
<td>$18.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Victoria's Secret. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Victoria's Secret compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Victoria's Secret's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Capture valuable insights into Victoria's Secret's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VSCO/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Victoria's Secret analyst ratings.</a>
<h2>Discovering Victoria's Secret: A Closer Look</h2>
Victoria's Secret &amp; Co is a specialty retailer of lingerie, pajamas, and beauty products with prestige fragrances and body care. It serves customers at its Lingerie and Beauty stores around the globe and online enabling them to shop the brand anywhere and anytime. The Company operates as a single segment designed to serve customers worldwide seamlessly through stores and online channels.
<h3>Victoria's Secret: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Negative Revenue Trend: Examining Victoria's Secret's financials over 3 months reveals challenges. As of 31 July, 2024, the company experienced a decline of approximately -0.7% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Victoria's Secret's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 2.26%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Victoria's Secret's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 7.15% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.71%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Victoria's Secret's debt-to-equity ratio surpasses industry norms, standing at 5.95. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VSCO

Deep Dive Into Victoria's Secret Stock: Analyst Perspectives (11 Ratings)

Urban Outfitters (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URBN#NASDAQ">URBN</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $47.75, a high estimate of $59.00, and a low estimate of $42.00. This upward trend is apparent, with the current average reflecting a 13.02% increase from the previous average price target of $42.25.
<img src="https://www.benzinga.com/files/images/story/2024/1732712477_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The perception of Urban Outfitters by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$46.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$59.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$42.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$44.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Urban Outfitters. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Urban Outfitters compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Urban Outfitters's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Urban Outfitters's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/URBN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Urban Outfitters analyst ratings.</a>
<h2>Discovering Urban Outfitters: A Closer Look</h2>
Founded in 1970, Philadelphia-based Urban Outfitters is an apparel and home goods retailer that operates more than 700 stores and e-commerce in the United States (87.5% of fiscal 2024 sales) and other regions. Its retail nameplates are Urban Outfitters, Free People, FP Movement, and Anthropologie. Retail accounted for 91% of fiscal 2024 revenue, but the firm also sells products through a wholesale operation, owns some restaurants, and operates a clothing rental and resale business called Nuuly (5% of sales). Urban Outfitters primarily markets to young adults and offers products in categories such as apparel (66% of sales), home goods (16% of sales), accessories (13% of sales), and more.
<h3>Urban Outfitters's Economic Impact: An Analysis</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Urban Outfitters displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately 6.27%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Urban Outfitters's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.69% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Urban Outfitters's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 5.34% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Urban Outfitters's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.78% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Urban Outfitters's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.49.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Urban Outfitters: Insights From 4 Financial Analysts

Baird analyst Michael Bellisario initiates coverage on Expedia Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) with a Outperform rating and announces Price Target of $225.

Initiation

EXPE

Baird Initiates Coverage On Expedia Group with Outperform Rating, Announces Price Target of $225

President-elect Donald Trump&#8216;s move to impose 25% tariffs on Canada can thwart the growth of the stock markets and affect corporate profits, inflation, transportation and oil marketing companies.
What Happened: This comes as Goldman Sachs head of commodities research, Daan Struyven told <a href="https://www.bloomberg.com/news/articles/2024-11-27/goldman-sees-significant-hit-to-us-from-trump-s-canada-tariffs">Bloomberg </a>that &#8220;The 25% levy on all products from Canada proposed by Trump would likely raise the price of fuels in the U.S.&#8221;
&#8220;He said that tariffs could significantly affect U.S. consumers, U.S. refiners, and Canadian producers," on Wednesday. In order for American producers to export more of their own oil, the U.S. imports almost 4 million barrels of Canadian crude a day. Struyven added that this could be a &#8220;negotiating tool.&#8221;
"Given the focus from Trump to lower energy costs, we think Canada tariffs are somewhat unlikely,&#8221; he added
U.S. and Canada along with Mexico signed the United States–Mexico–Canada Agreement as an update to North American Free Trade Agreement, or NAFTA in 2020. It allowed for mostly duty-free trade between the three countries. Trump&#8217;s threat of tariffs would seem to violate the terms.
Also read: <a href="https://www.benzinga.com/general/market-summary/24/11/42206673/trumps-running-mate-vice-president-pick-and-venture-capitalist-jd-vance-holds-etfs-bitcoin-and-more-here-is-a-look-at-his-portfolio">JD Vance&#8217;s Investment Playbook Has Bitcoin And ETFs: Here&#8217;s What Else The VP-Elect Is Betting On</a>
Why It Matters: As higher Canadian tariffs could raise the domestic fuel prices in the U.S., it will impact the corporate profits of many companies and increase both, consumer and producer price inflation.
The input costs of transportation and oil marketing companies can increase, which may lower their profits and stock prices. Also, investors may want to short the stocks of these companies when oil prices are high.
A few of the many transportation companies that would get affected by this include, Union Pacific Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNP#NYSE">UNP</a>), CSX Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>), Uber Technologies Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>), Old Dominion Freight Line Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>), TFI International Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFII#NYSE">TFII</a>), Knight-Swift Transportation Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>), XPO Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) and Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>).
Similarly, companies like Chevron Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVX#NYSE">CVX</a>), Exxon Mobil Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>), BP plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BP#NYSE">BP</a>), TotalEnergies SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTE#NYSE">TTE</a>), Shell PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>), Enbridge Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENB#NYSE">ENB</a>), and ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) are a few oil marketing companies that my bear the direct brunt of this.
Read next: <a href="https://www.benzinga.com/markets/equities/24/11/42186167/michael-saylors-microstrategy-convertible-notes-to-buy-bitcoin-offer-no-interest-so-why-are-investors-rushing-to-buy-them">Michael Saylor&#8217;s MicroStrategy Convertible Notes To Buy Bitcoin Offer No Interest, So Why Are Investors Rushing To Buy Them?</a>
Photo by Hamara via Shutterstock

Macro Economic Events

Macro Notification

Market Summary

Economics

ODFL

SHEL

TFII

UBER

Trump's Tariff Threat To Canada May Disrupt Oil Markets, Inflate Prices: 'Would Likely Raise The Price Of Fuels,' Says Analyst

Telsey Advisory Group analyst Joseph Feldman maintains Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) with a Outperform and raises the price target from $62 to $65.

Telsey Advisory Group Maintains Outperform on Kroger, Raises Price Target to $65

7 analysts have expressed a variety of opinions on Vince Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VNCE#NYSE">VNCE</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Vince Holding, revealing an average target of $3.0, a high estimate of $3.00, and a low estimate of $3.00. This current average is unchanged from the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1732712463_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Vince Holding by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
<tr>
<td>Eric Beder</td>
<td>Small Cap Consumer Research</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.00</td>
<td>$3.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Vince Holding. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Vince Holding compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Vince Holding's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Vince Holding's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/VNCE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Vince Holding analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Vince Holding's Background</h2>
Vince Holding Corp is a fashion brand that is engaged in wholesale and retail delivery of luxury essentials like women's and men's apparel, women's and men's footwear, and handbags. Its offers women's collections of luxurious cashmere sweaters and silk blouses, leather and suede leggings and jackets, dresses, denim, pants, tanks and t-shirts, and a growing assortment of outerwear. It focuses on developing an elevated collection of Vince apparel and accessories to serve the luxurious need of the customer. The company manages its business in three segments namely Vince Wholesale, Vince Direct-to-consumer, and Rebecca Taylor and Parker segment. It operates its e-commerce business through its website. Majority of its revenue generated from Vince Wholesale segment.
<h3>Vince Holding: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Vince Holding displayed positive results in 3 months. As of 31 July, 2024, the company achieved a solid revenue growth rate of approximately 6.8%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Vince Holding's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 0.77%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Vince Holding's ROE stands out, surpassing industry averages. With an impressive ROE of 1.09%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Vince Holding's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.24%, the company showcases efficient use of assets and strong financial health.
Debt Management: Vince Holding's debt-to-equity ratio is notably higher than the industry average. With a ratio of 2.76, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VNCE

Vince Holding Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bluejay Diagnostics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bjdx-stock-quote/">BJDX</a>) just reported results for the fourth quarter of 2023.<ul><li>Bluejay Diagnostics reported earnings per share of -$1.78. This was below the analyst estimate for EPS of -68 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/03/bjdx-stock-earnings-bluejay-diagnostics-for-q4-of-2023/">BJDX Stock Earnings: Bluejay Diagnostics Misses EPS for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BJDX Stock Earnings: Bluejay Diagnostics Misses EPS for Q4 2023

Bluejay Diagnostics (BJDX) has issued an announcement. Bluejay Diagnostics, Inc. has ended its agreement with DLA, LLC, leading to the departure of...

Bluejay Diagnostics Announces CFO Change and Stockholders' Meeting Date

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We are starting off Wednesday with a breakdown of the biggest pre-market stock movers traders will want to read about!



Moving shares are earnings reports, a reverse stock split and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Chicken Soup for the Soul (NASDAQ:<a href="https://investorplace.com/stock-quotes/csse-stock-quote/">CSSE</a>) stock is rocketing more than 68% alongside heavy pre-market trading.</li>



<li>Zapata Computing (NASDAQ:<a href="https://investorplace.com/stock-quotes/zpta-stock-quote/">ZPTA</a>) shares are soaring over 26% alongside <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318251841&amp;type=PDF&amp;symbol=ZPTA&amp;cdn=84fce7fb704e6ef8a8fd234dc0d1a286&amp;companyName=Zapata+Computing+Holdings+Inc.&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-04-24">secondary offering news</a>.</li>



<li>GraniteShares 2x Long TSLA Daily ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLR#NASDAQ">TSLR</a>) stock is surging close to 24% following Tesla&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsla-stock-quote/">TSLA</a>) <a href="https://www.marketwatch.com/livecoverage/tesla-earnings-ev-elon-musk-q1-stock-cybertruck-robotaxi/">latest earnings report</a>.</li>



<li>T-REX 2X Long Tesla Daily Target ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/tslt-stock-quote/">TSLT</a>) shares are gaining more than 22% for the same reason. </li>



<li>Direxion Daily TSLA Bull 2X Shares (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsll-stock-quote/">TSLL</a>) stock is rising over 22% alongside TSLA earnings.</li>



<li>XBP Europe (NASDAQ:<a href="https://investorplace.com/stock-quotes/xbp-stock-quote/">XBP</a>) shares are increasing more than 22% without any clear news this morning.</li>



<li>B. Riley Financial (NASDAQ:<a href="https://investorplace.com/stock-quotes/rily-stock-quote/">RILY</a>) stock is climbing over 19% with the release of its <a href="https://www.prnewswire.com/news-releases/b-riley-financial-files-2023-annual-report-on-form-10-k-302125970.html">2023 annual report</a>.</li>



<li>Vertiv (NYSE:<a href="https://investorplace.com/stock-quotes/vrt-stock-quote/">VRT</a>) shares are heading more than 16% higher after <a href="https://www.investors.com/news/vertiv-spikes-on-earnings-ai-stocks-nvidia-super-micro/">releasing its Q1 earnings report</a>.</li>



<li>AudioEye (NASDAQ:<a href="https://investorplace.com/stock-quotes/aeye-stock-quote/">AEYE</a>) stock is getting an over 13% boost with its <a href="https://qz.com/audioeye-q1-earnings-snapshot-1851430210">Q1 earnings release</a>.</li>



<li>WiMi Hologram Cloud (NASDAQ:<a href="https://investorplace.com/stock-quotes/wimi-stock-quote/">WIMI</a>) shares are up more than 13% following a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318249494&amp;type=PDF&amp;symbol=WIMI&amp;cdn=21b188804ad8e2afae8ca53a0c6f207e&amp;companyName=WiMi+Hologram+Cloud+Inc.&amp;formType=6-K&amp;formDescription=Report+of+foreign+private+issuer+pursuant+to+Rule+13a-16+or+15d-16+under+the+Securities+Exchange+Act+of+1934&amp;dateFiled=2024-04-23">goodwill impairment assessment</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Evotec (NASDAQ:<a href="https://investorplace.com/stock-quotes/evo-stock-quote/">EVO</a>) shares are plummeting more than 35% alongside its <a href="https://www.nasdaq.com/press-release/evotec-presents-fiscal-year-2023-results-and-announces-priority-reset-to-focus-on">latest earnings report</a>.</li>



<li>Fabrinet (NYSE:<a href="https://investorplace.com/stock-quotes/fn-stock-quote/">FN</a>) stock is diving over 24% after <a href="https://www.nasdaq.com/press-release/fabrinet-to-announce-third-quarter-fiscal-year-2024-financial-results-on-may-6-2024">announcing its earnings date</a>.</li>



<li>GraniteShares 2x Short TSLA Daily ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsdd-stock-quote/">TSDD</a>) shares are dropping more than 23% after TSLA&rsquo;s earnings report.</li>



<li>T-Rex 2X Inverse Tesla Daily Target ETF (NASDAQ:<a href="https://investorplace.com/stock-quotes/tslz-stock-quote/">TSLZ</a>) stock is falling over 23% for the same reason.</li>



<li>Bluejay Diagnostics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bjdx-stock-quote/">BJDX</a>) shares are sliding 20% without any clear news.</li>



<li>Kiora Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/kprx-stock-quote/">KPRX</a>) stock is decreasing more than 19% today.</li>



<li>Mawson Infrastructure (NASDAQ:<a href="https://investorplace.com/stock-quotes/migi-stock-quote/">MIGI</a>) shares are slipping nearly 16% on Wednesday morning.</li>



<li>Applied DNA Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/apdn-stock-quote/">APDN</a>) stock is dipping over 15% ahead of a <a href="https://www.nasdaq.com/press-release/applied-dna-announces-1-for-20-reverse-stock-split-2024-04-22">reverse stock split tomorrow</a>.</li>



<li>BiomX (NYSEMKT:<a href="https://investorplace.com/stock-quotes/phge-stock-quote/">PHGE</a>) shares are declining more than 14% <a href="https://www.nasdaq.com/press-release/biomx-to-present-data-from-phase-1b-2a-study-of-bx004-for-the-treatment-of-cystic">following a rally yesterday</a>.</li>



<li>Ostin Technology (NASDAQ:<a href="https://investorplace.com/stock-quotes/ost-stock-quote/">OST</a>) stock closes out our pre-market stock movers down over 11%.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-april-24th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
We have all of the biggest pre-market stock movers that traders will want to read about on Monday morning!



Moving stocks this morning an investor update, clinical trial news, a private offering and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Scinai Immunotherapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/scni-stock-quote/">SCNI</a>) stock is rocketing more than 69% alongside heavy pre-market trading.</li>



<li>Schmid Group (NASDAQ:<a href="https://investorplace.com/stock-quotes/shmd-stock-quote/">SHMD</a>) shares are soaring 40% without any clear news this morning.</li>



<li>ENDRA Life Sciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/ndra-stock-quote/">NDRA</a>) stock is surging over 36% alongside an <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318395592&amp;type=PDF&amp;symbol=NDRA&amp;cdn=4506ae3b1a739822361489bedc53ef84&amp;companyName=ENDRA+Life+Sciences+Inc.&amp;formType=SC+13G&amp;formDescription=Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-06-14">investor stake update</a>.</li>



<li>Maxeon Solar Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/maxn-stock-quote/">MAXN</a>) shares are rising more than 21% with strong early morning trading.</li>



<li>Srivaru (NASDAQ:<a href="https://investorplace.com/stock-quotes/svmh-stock-quote/">SVMH</a>) stock is increasing over 18% as it continues to <a href="https://investorplace.com/2024/06/why-is-srivaru-svmh-stock-up-122-today/">rally on e-bike news</a>.</li>



<li>Nurix Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/nrix-stock-quote/">NRIX</a>) shares are gaining 17% on <a href="https://www.marketwatch.com/story/nurix-therapeutics-shares-rise-on-positive-leukemia-drug-results-66b9d524?mod=investing">positive drug results</a>.</li>



<li>Icecure Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/iccm-stock-quote/">ICCM</a>) stock is getting a 14% boost with it still rallying on <a href="https://www.nasdaq.com/press-release/positive-data-icecures-kidney-cancer-clinical-study-presented-interventional">kidney cancer study data</a>.</li>



<li>Kineta (NASDAQ:<a href="https://investorplace.com/stock-quotes/ka-stock-quote/">KA</a>) shares are heading more than 13% higher with heavy trading today.</li>



<li>XTL Biopharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/xtlb-stock-quote/">XTLB</a>) stock is jumping over 12% this morning.</li>



<li>Conn&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/conn-stock-quote/">CONN</a>) shares are up more than 11% today.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Kaival Brands Innovations (NASDAQ:<a href="https://investorplace.com/stock-quotes/kavl-stock-quote/">KAVL</a>) stock is plummeting more than 35% after a massive rally on Friday.</li>



<li>Sonim Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/sonm-stock-quote/">SONM</a>) shares are diving over 25% this morning.</li>



<li>AMC Networks (NASDAQ:<a href="https://investorplace.com/stock-quotes/amcx-stock-quote/">AMCX</a>) stock is tumbling more than 23% after <a href="https://www.nasdaq.com/press-release/amc-networks-inc-announces-private-offering-125-million-convertible-senior-notes-2024">announcing a private offering</a>.</li>



<li>Bluejay Diagnostics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bjdx-stock-quote/">BJDX</a>) shares are taking an over 17% beating despite a lack of news.</li>



<li>Northann (NYSEMKT:<a href="https://investorplace.com/stock-quotes/ncl-stock-quote/">NCL</a>) stock is falling close to 14% without any news to report.</li>



<li>Zapp Electric Vehicles (NASDAQ:<a href="https://investorplace.com/stock-quotes/zapp-stock-quote/">ZAPP</a>) shares are dropping more than 13% as it <a href="https://investorplace.com/2024/06/why-is-zapp-electric-vehicles-zapp-stock-up-173-today/">comes off a rally last week</a>.</li>



<li>Aptevo Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/apvo-stock-quote/">APVO</a>) stock is decreasing over 13% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318396271&amp;type=PDF&amp;symbol=APVO&amp;cdn=21e6c068c48621c307f0f74bc8553007&amp;companyName=Aptevo+Therapeutics+Inc.&amp;formType=S-1&amp;formDescription=Registration+statement+under+Securities+Act+of+1933&amp;dateFiled=2024-06-14">proposed public offering</a>.</li>



<li>Feutune Light Acquisition (NASDAQ:<a href="https://investorplace.com/stock-quotes/flfv-stock-quote/">FLFV</a>) shares are slipping almost 12% on Monday.</li>



<li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock is dipping more than 11% on <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318396398&amp;type=PDF&amp;symbol=VLCN&amp;cdn=980b1d9c3f018f25ac11de4d0e102b66&amp;companyName=Volcon+Inc.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-14">a delisting notice</a>.</li>



<li>Holdco Nuvo (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuvo-stock-quote/">NUVO</a>) shares close out our pre-market stock movers down over 11% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-monday-june-17th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

Bluejay Diagnostics announces 1-for-8 reverse stock split

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth checking out on Thursday as we dig into all of the news moving shares this morning!



Moving stocks are public offering updates, new investments an earnings report and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Assure (NASDAQ:<a href="https://investorplace.com/stock-quotes/ionm-stock-quote/">IONM</a>) stock is rocketing more than 128% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318417463&amp;type=PDF&amp;symbol=IONM&amp;cdn=8d8708e472ad2a1117d6e2e1ea234033&amp;companyName=Assure+Holdings+Corp.&amp;formType=RW&amp;formDescription=Registration+Withdrawal+Request&amp;dateFiled=2024-06-26">withdrawing a proposed public offering</a>.</li>



<li>Vigil Neuroscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/vigl-stock-quote/">VIGL</a>) shares are soaring over 40% on a <a href="https://www.globenewswire.com/news-release/2024/06/27/2904902/0/en/Vigil-Neuroscience-Announces-40-Million-Strategic-Investment-from-Sanofi.html">$40 million investment</a>.</li>



<li>CASI Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/casi-stock-quote/">CASI</a>) stock is surging more than 31% on a <a href="https://www.prnewswire.com/news-releases/casi-pharmaceuticals-announces-15-million-private-placement-financing-by-venrock-healthcare-capital-partners-foresite-capital-panacea-venture-and-dr-wei-wu-he-302183230.html">$15 million private placement</a>.</li>



<li>Entero Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ento-stock-quote/">ENTO</a>) shares are gaining over 26% on a <a href="https://www.nasdaq.com/press-release/entero-therapeutics-announces-peer-reviewed-publication-unveiling-novel-algorithm">peer-reviewed publication</a>.</li>



<li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) stock is increasing more than 24% as it <a href="https://investorplace.com/2024/06/faraday-future-ffie-stock-soars-80-following-rivian-volkswagen-deal/">continues a recent rally</a>.</li>



<li>Incannex Healthcare (NASDAQ:<a href="https://investorplace.com/stock-quotes/ixhl-stock-quote/">IXHL</a>) shares are jumping over 23% despite a lack of news this morning.</li>



<li>Geovax Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/govx-stock-quote/">GOVX</a>) stock is climbing more than 21% without any clear news this morning.</li>



<li>Fresh Vine Wine (NYSEMKT:<a href="https://investorplace.com/stock-quotes/vine-stock-quote/">VINE</a>) shares are heading close to 17% higher with heavy pre-market trading.</li>



<li>Phunware (NASDAQ:<a href="https://investorplace.com/stock-quotes/phun-stock-quote/">PHUN</a>) stock is getting an over 15% boost without any obvious news to report.</li>



<li>Hyzon Motors (NASDAQ:<a href="https://investorplace.com/stock-quotes/hyzn-stock-quote/">HYZN</a>) shares are up nearly 15% with strong trading this morning.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Branchout Food (NASDAQ:<a href="https://investorplace.com/stock-quotes/bof-stock-quote/">BOF</a>) stock is plummeting more than 37% after <a href="https://www.nasdaq.com/press-release/branchout-food-prices-14-million-follow-public-offering-2024-06-26">pricing a follow-on offering</a>.</li>



<li>Tonix Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/tnxp-stock-quote/">TNXP</a>) shares are diving over 28% on a <a href="https://www.stocktitan.net/news/TNXP/tonix-pharmaceuticals-announces-proposed-public-d6yhuinwfxm9.html">proposed public offering</a>.</li>



<li>Bluejay Diagnostics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bjdx-stock-quote/">BJDX</a>) stock is tumbling more than 21% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318418078&amp;type=PDF&amp;symbol=BJDX&amp;cdn=14a15ef82de2ebc313ddbbf7cad3f31c&amp;companyName=Bluejay+Diagnostics+Inc.&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-06-26">effecting a public offering</a>.</li>



<li>Immutep (NASDAQ:<a href="https://investorplace.com/stock-quotes/immp-stock-quote/">IMMP</a>) shares are taking an over 17% beating without any apparent news today.</li>



<li>VSee Health (NASDAQ:<a href="https://investorplace.com/stock-quotes/vsee-stock-quote/">VSEE</a>) stock is slipping more than 17% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318417950&amp;type=PDF&amp;symbol=VSEE&amp;cdn=a8750adb0a7c7d12db86db6bfac8e49b&amp;companyName=VSee+Health+Inc.&amp;formType=4&amp;formDescription=Statement+of+changes+in+beneficial+ownership+of+securities&amp;dateFiled=2024-06-26">alongside recent insider trading</a>.</li>



<li>Swvl (NASDAQ:<a href="https://investorplace.com/stock-quotes/swvl-stock-quote/">SWVL</a>) shares are dropping over 16% on Thursday morning.</li>



<li>Levi Strauss (NYSE:<a href="https://investorplace.com/stock-quotes/levi-stock-quote/">LEVI</a>) stock is decreasing more than 16% with its <a href="https://www.cnbc.com/2024/06/26/levi-levi-earnings-q2-2024.html">Q2 earnings report</a>.</li>



<li>International Paper (NYSE:<a href="https://investorplace.com/stock-quotes/ip-stock-quote/">IP</a>) shares are falling over 15% today.</li>



<li>Recursion Pharmaceuticals (NASDAQ:<a href="https://investorplace.com/stock-quotes/rxrx-stock-quote/">RXRX</a>) stock is slipping more than 14% after <a href="https://www.stocktitan.net/news/RXRX/recursion-announces-pricing-of-200-million-public-offering-of-class-49il22g17787.html">pricing a public offering</a>.</li>



<li>KraneShares California Carbon Allowance Strategy ETF (NYSEARCA:<a href="https://investorplace.com/stock-quotes/kcca-stock-quote/">KCCA</a>) shares close out our pre-market stock movers down over 13%. </li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-thursday-june-27th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Bluejay Diagnostics (NASDAQ:<a href="https://investorplace.com/stock-quotes/bjdx-stock-quote/">BJDX</a>) just reported results for the second quarter of 2024.<ul><li>Bluejay Diagnostics reported earnings per share of -$5.12. This was below the analyst estimate for EPS of -72 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/bjdx-stock-earnings-bluejay-diagnostics-for-q2-of-2024/">BJDX Stock Earnings: Bluejay Diagnostics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BJDX Stock Earnings: Bluejay Diagnostics Misses EPS for Q2 2024

Bluejay Diagnostics announces 1 for 50 reverse stock split

Bluejay Diagnostics (BJDX) announced that the company's Board of Directors has approved a reverse stock split of its shares of common stock at a ra...

Bluejay Diagnostics announces 1-for-50 reverse stock split

19:50 EST Bluejay Diagnostics (BJDX) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving ...

Bluejay Diagnostics Inc trading halted, news pending

AEYE

AMCX

APDN

APVO

BJDX

CASI

CONN

CSSE

ENTO

FFIE

FLFV

GOVX

HYZN

ICCM

IMMP

IONM

IXHL

KAVL

KCCA

KPRX

LEVI

MAXN

MIGI

NDRA

NRIX

NUVO

PHGE

PHUN

RILY

RXRX

SCNI

SHMD

SONM

SVMH

SWVL

TNXP

TSDD

TSLA

TSLL

TSLR

TSLT

TSLZ

VIGL

VINE

VLCN

VSEE

WIMI

XTLB

ZAPP

ZPTA

Press Releases

Bluejay Diagnostics, Inc. Announces Initiation of Multicenter Clinical Study Evaluating Symphony IL-6 in Sepsis Patients (SYMON Study)

Financing

Bluejay Diagnostics Announces Pricing of $3.5 Million Public Offering

Bluejay Diagnostics Announces Closing of $3.5 Million Public Offering

Bluejay Diagnostics Announces Reverse Stock Split

SYMON-I Study of Symphony IL-6 Suggests Prediction of Mortality in Sepsis Patients

Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering

Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering

Bitech Technologies (OTCQB: BTTC) Appoints Montgomery Bannerman to Drive Strategic Growth in Renewable Energy – see other stocks inside….

Comments

Bluejay Diagnostics

ニュース

最新ニュース Bluejay Diagnostics (NASDAQ:BJDX) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル